Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-05-11

FDA Approved: TIGLUTIK — Supplemental Application (EDW PHARMA, INC)

View source ↗

Summary

FDA approved a supplemental application for Tiglutik (riluzole) submitted by EDW Pharma, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TIGLUTIK (RILUZOLE)

Snippet

SUPPL AP for TIGLUTIK (RILUZOLE)